N4 PHARMA PLC — Director's Dealing 2014

Nov 26, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0399Y

Verona Pharma PLC

26 November 2014

Verona Pharma plc

("Verona Pharma" or the "Company")

Director's Dealing

26 November 2014, Cardiff, UK- Verona Pharma plc (AIM: VRP.L) (the "Company") received notification on 25 November 2014 that on that date, Mr Stuart Bottomley, a non-executive director of the Company, acquired via his SIPP an interest in 500,000 ordinary shares of 0.1p each in the Company ("Ordinary Shares") at a price of 1.45 pence per share.

Following the acquisition, Mr. Bottomley will have an interest in the Company of 18,750,000 Ordinary Shares, representing 1.86% of the Company's issued ordinary share capital. 

-Ends-

For further information please contact:

Verona Pharma plc	Tel: +44 (0) 20 7863 3300
Jan-Anders Karlsson, CEO
N+1 Singer	Tel: +44 (0)20 7496 3000
Aubrey Powell / Jen Boorer
FTI Consulting	Tel: +44 (0)20 3727 1000
Julia Phillips / Simon Conway

Notes to Editors

About Verona Pharma plc

Verona Pharma plc is a UK-based clinical stage biopharmaceutical company focused on the development of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as COPD, asthma and cystic fibrosis. Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in Phase II trials as a nebulised treatment for acute exacerbations of COPD in the hospital setting. The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both bronchodilator and anti-inflammatory effects, which are essential to the improvement of patients with COPD and asthma. Verona Pharma is also building a broader franchise around RPL554 to maximise its value, both to patients and to investors. This includes the very significant markets for COPD and asthma maintenance therapy. The Company is also exploring the potential of the drug in different diseases, such as cystic fibrosis, where it is in pre-clinical testing. 

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSBQLFLZFFFFBF